Please assess the completion status of the following clinical trial:

Trial Title: Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (US Trial)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DEVICE_FEASIBILITY
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Enrollment within 24 hours of hospital admission of patients diagnosed with COVID-19~* Patients with oxygen saturation less than 93 % on room air~* Shortness of breath, with symptom onset within the previous 8 days.~* Female subjects of childbearing potential should take adequate measures to avoid pregnancy~* Signed informed consent by the subject~Exclusion Criteria:~* Patients who are treated with or require high flow nasal cannula, CPAP, intubation, mechanical ventilation, or tracheostomy~* Diagnosis of acute respiratory distress syndrome~* Subjects diagnosed with immunodeficiency, with history of congestive or unstable heart disease, left ventricular dysfunction or myocardial damage, severe pulmonary hypertension and/or unstable hypertension~* Patients receiving drugs that have contraindications with NO.~* Breastfeeding or pregnancy as evidenced by a positive pregnancy test.~* Patients with active pulmonary malignancy or lung transplant~* Patients with a history of frequent epistaxis or significant hemoptysis

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Inhaled NO delivered using LungFit™ in addition to SST (Type: EXPERIMENTAL): Patients will receive 80 ppm iNO for 40 min 4 times a day using LungFit™ device in addition to the standard of care.
- Standard of care (Type: NO_INTERVENTION): Control - Standard of care

Based on this trial design, predict the completion outcome and termination type (if applicable).